Novelix promoters acquire 950,000 shares via warrant conversion

Promoters of Novelix Pharmaceuticals Limited increased their stake by acquiring 950,000 equity shares through the conversion of warrants on May 29, 2026. The acquisition, executed via a preferential allotment, significantly alters the company's shareholding pattern and strengthens promoter control. Srinidhi Fine Chemicals LLP accounted for the largest portion of this increase, acquiring 800,000 shares, while Narahari Belide acquired 150,000 shares.

The disclosures were submitted to BSE Limited on June 01, 2026, and June 02, 2026, in compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filings detailed the transactions involving promoters and members of the promoter group.

Shareholding Details

The acquisition involved the conversion of warrants held by various promoter group entities. Prior to the acquisition, the company's equity share capital stood at ₹210,850,000, comprising 21,085,000 equity shares of ₹10 each. Following the allotment, the equity share capital increased to ₹238,950,000, comprising 23,895,000 equity shares of ₹10 each.

The following table outlines the changes in shareholding for the key acquirers disclosed:

Acquirer	Shares Before	Shares Acquired	Shares After	% Holding After
Srinidhi Fine Chemicals LLP	7,102,000	800,000	7,902,000	33.07 %
Narahari Belide	650,000	150,000	800,000	3.35 %
Total	7,752,000	950,000	8,702,000	**36.42 %

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.28%	+0.63%	-1.14%	-17.78%	+94.70%	+580.00%

Novelix Pharmaceuticals Limited will hold a board meeting on June 4, 2026, to consider the preferential issuance of securities and approve the draft notice for an Extra Ordinary General Meeting (EGM). The meeting, scheduled at the company's registered office, will also determine the date, time, and venue for the EGM and appoint a scrutinizer to oversee the e-voting process. The trading window for designated persons and their relatives has been closed from June 1, 2026, and will remain shut until 48 hours after the announcement is made public.

The board's agenda includes evaluating the issuance of securities on a preferential basis in accordance with the Companies Act, 2013, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018. Any such issuance will be subject to necessary regulatory and statutory approvals, as well as shareholder authorization. The company has not yet disclosed the specific size or pricing of the proposed issue.

Agenda for Board Meeting

The meeting will cover the following key items:

Consideration and approval of preferential issuance of securities.
Adoption and approval of the draft notice for the EGM.
Fixation of the day, date, time, and venue for the EGM.
Appointment of a scrutinizer for the e-voting process.

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the company has closed its trading window for all designated persons and their immediate relatives. This restriction is effective from June 1, 2026, and will continue until 48 hours after the official announcement is made available to the public. All relevant personnel have been instructed to refrain from trading in the company's securities during this period.

The board meeting follows Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The outcomes of the meeting, particularly regarding the preferential allotment and EGM schedule, will require shareholder approval before implementation.